Details for New Drug Application (NDA): 211219
The generic ingredient in ESLICARBAZEPINE ACETATE is eslicarbazepine acetate. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the eslicarbazepine acetate profile page.
Summary for 211219
| Tradename: | ESLICARBAZEPINE ACETATE |
| Applicant: | Jubilant Generics |
| Ingredient: | eslicarbazepine acetate |
| Patents: | 0 |
Pharmacology for NDA: 211219
| Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 211219
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ESLICARBAZEPINE ACETATE | eslicarbazepine acetate | TABLET;ORAL | 211219 | ANDA | Jubilant Cadista Pharmaceuticals Inc. | 59746-717 | 59746-717-10 | 1000 TABLET in 1 BOTTLE (59746-717-10) |
| ESLICARBAZEPINE ACETATE | eslicarbazepine acetate | TABLET;ORAL | 211219 | ANDA | Jubilant Cadista Pharmaceuticals Inc. | 59746-717 | 59746-717-30 | 30 TABLET in 1 BOTTLE (59746-717-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Aug 4, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 400MG | ||||
| Approval Date: | Aug 4, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 600MG | ||||
| Approval Date: | Aug 4, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
